Reduced Mortality in COVID‐19 Patients Treated With Inhaled Extracellular Vesicles Expressing CD24

Key Points

• The aim was to assess the effects of inhaled extracellular vesicles expressing CD24 on mortality in COVID-19 patients.
• Clinical trial involving COVID-19 patients
• Intervention with inhaled extracellular vesicles
• Assessment of mortality as a primary outcome
• Treatment with inhaled extracellular vesicles expressing CD24 significantly reduced mortality rates in patients with COVID-19.